Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067782 · ClinicalTrials.gov registry record · Phase 3
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00067782 is a Phase 3 study that has completed, run by Bristol-Myers Squibb.
The verdict
NCT00067782, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.
Interventions
- DRUG Atazanavir (immediate switch)
- DRUG Atazanavir (Week 24 switch)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-12 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067782
The ClinicalTrials.gov registry entry for NCT00067782 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atazanavir (immediate switch) is the first listed.
NCT00067782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067782 about?
NCT00067782 is a clinical study titled "A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy". The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.
What is the current status of trial NCT00067782?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-12. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00067782?
The interventions under investigation include: Atazanavir (immediate switch) (DRUG), Atazanavir (Week 24 switch) (DRUG).
Who is sponsoring clinical trial NCT00067782?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.